Multidisciplinary Association of Psychedelic Studies (MAPS) International Therapist Education Program

65 hours of education Online content (15 hours) Asynchronous, self-paced coursework to be completed by the assigned deadline In person retreat (50 hours, including Grof®Breathwork) MDMA-assisted therapy MDMA-assisted therapy involves using prescribed MDMA doses alongside therapy sessions. Research suggests it may enhance treatment effectiveness for Postraumatic Distress Disorder (PTSD). Staff Marcela O’talora and Bruce Poulter are experienced trauma specialists and trainers for MAPS’ MDMA-assisted therapy training, with extensive backgrounds in private practice, research, and public health. Location Nestled in the Alps, Kientalerhof offers a serene retreat in the stunning Kiental Valley. Known for its holistic healing and transformative programs, it’s a haven for growth and rejuvenation Applicants must be able to commit to uninterrupted participation in all live education components. Participation includes viewing and discussing emotionally intense treatment sessions and participating in small group breakouts as well as practice scenarios. Participants are asked to clear their calendar and participate fully. Full attendance is required to receive a certificate of participation. Group activities will be supervised by MAPS-trained teaching assistents (TAs). Every trainee will facilitate and experience one breathwork session supported by the TAs. Applicants can apply for the education program if they are authorized to practice therapy according to local regulation. This includes if you are a psychologist, psychotherapist, physicians, or have another mental health background. Applicants who have experience working with people with Posttraumatic Stress Disorder will be prioritized. In Switzerland, psychedelic-assisted therapy is legally permissible under specific conditions. The Federal Act on Narcotics and Psychotropic Substances (NarcA) regulates the use of narcotics and psychotropic substances, including psychedelics like MDMA, LSD, and psilocybin. While these substances are generally prohibited, the NarcA allows for their restricted medical use, provided certain criteria are met. To administer psychedelics in a therapeutic setting, therapists must obtain an exemption permit from the Federal Office of Public Health (FOPH). This permit is granted on a case-by-case basis and requires that existing treatments are ineffective and that preliminary scientific evidence suggests the efficacy of the scheduled drug for the particular condition. Participants will receive proof of participation and completion of this training course. However, please note this is not a certification course to deliver MDMA-assisted therapy. There are currently no certification standards for any psychedelic-assisted therapy given the investigational status of this modality, which has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.

Number of Attendees: 50